GnRH I CRISPR/Cas9 KO Plasmid (h): sc-401425
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GnRH I CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the GnRH I genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: GnRH I Antibody (HU11B): sc-32292
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GnRH I CRISPR/Cas9 KO Plasmid (h) | sc-401425 | 20 µg | $397.00 |
Overview
GNRH1 encodes gonadotropin-releasing hormone I (GnRH I), a hypothalamic decapeptide that initiates pulsatile signaling to pituitary gonadotrophs via the GnRHR GPCR, driving phospholipase C/IP3–DAG/Ca2+ pathways and MAPK activation. This signaling regulates synthesis and secretion of luteinizing hormone and follicle-stimulating hormone, coordinating reproductive axis function, pubertal timing, and fertility. Altered GNRH1 expression or peptide processing has been implicated in disorders of hypothalamic–pituitary–gonadal axis regulation, including congenital hypogonadotropic hypogonadism and related reproductive endocrine phenotypes. In cell and tissue models, GNRH1 is studied for neuroendocrine differentiation, hormone secretion dynamics, and transcriptional control of reproductive signaling programs.
GnRH I CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the GNRH1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the GNRH1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the GNRH1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish GnRH I protein expression.
This CRISPR knockout system enables efficient generation of GNRH1-deficient cell models for investigation of GnRH I signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting GNRH1 exon(s) critical for GnRH I function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple GNRH1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by GnRH I CRISPR/Cas9 KO Plasmid (h) and GnRH I CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the GNRH1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by GnRH I HDR Plasmid (h) and GnRH I HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by GNRH1 homology arms to support homology-directed repair at defined GNRH1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.